Sanz G F, Sanz M A, Rafecas F J, Martínez J A, Martín-Aragonés G, Marty M L
Cancer Treat Rep. 1986 Nov;70(11):1321-3.
Nineteen adolescents and adults with relapsed acute lymphoblastic leukemia (ALL) were treated with teniposide (VM-26) plus cytarabine (ara-C). Eight patients (42%) achieved complete remission. Infection and bleeding secondary to myelosuppression were the most serious complications seen. Responders received periodic reinductions with VM-26 and ara-C, but all relapsed within 16 weeks from remission. Our data demonstrate the effectiveness of combination chemotherapy with VM-26 plus ara-C in adolescent and adult ALL in relapse and suggest testing of this combination in first-line protocols. For remission maintenance, the association of other drug combinations is necessary.
19例复发急性淋巴细胞白血病（ALL）的青少年和成人患者接受了替尼泊苷（VM - 26）联合阿糖胞苷（ara - C）治疗。8例患者（42%）获得完全缓解。骨髓抑制继发的感染和出血是最严重的并发症。缓解者接受了VM - 26和ara - C的定期再诱导治疗，但均在缓解后16周内复发。我们的数据表明，VM - 26联合ara - C的联合化疗对复发的青少年和成人ALL有效，并建议在一线方案中测试这种联合用药。对于缓解期维持，需要联合其他药物组合。
